Horizon scanning: Drisapersen linked to serious side effects and hospitalisation according to safety data from trial investigating the drug in Duchenne muscular dystrophy

Source: BioSpace Area: News BioSpace reports that patients enrolled in an early stage trial investigating the use of drisapersen (GSK-2402968) in Duchenne muscular dystrophy (DMD) have been hospitalised due to kidney toxicity and low platelet counts. The report is based on data presented at a research meeting in Rome. GlaxSmithKline (GSK) has released some safety data from early stage clinical trials previously too and these mainly reported cases of proteinuria and decreased thrombocytes. According to the BioSpace report, four DMD) patients treated with drisapersen required hospitalisation due to thrombocytopenia and "several" patients with "severe proteinuria" also required hospitalisation. When contacted by BioSpace, the company confirmed that the DMD patients hospitalised were all enrolled in the ongoing phase II and phase III clinical trials of drisapersen and added that the hospitalisations had occurred "over the last two years" and had been discussed at previous medical meetings. No further information is ...
Source: NeLM - News - Category: Drugs & Pharmacology Source Type: news